• Alosetron in Intestinal Signaling Research

  2026-08-18

  Alosetron provides a reversible pharmacologic way to interrogate 5-HT3 receptor signaling alongside intestinal stem-cell polarity and fate assays. This workflow separates serotonin-dependent effects on epithelial behavior, gastrointestinal motility modulation, and visceral pain signaling research from the CDC42–YAP–EGFR–mTOR mechanism described in the reference study.

• Recombinant Mouse Sonic Hedgehog: Assay Workflow

  2026-08-17

  Build more reproducible SHH signaling experiments with a workflow spanning protein preparation, alkaline phosphatase induction, and developmental explant assays. The approach also translates comparative genital-tubercle findings into practical design choices for limb and brain patterning studies and congenital malformation research.

• Lithium, Rab11a, and Exosomal Wnt10a in Osteogenesis

  2026-08-17

  The reference study identifies a mechanism in which lithium enhances BMSC osteogenesis by promoting Rab11a/Rab11FIP1-dependent secretion of exosomal Wnt10a and activating Wnt/β-catenin signaling. Its comparison of lithium-conditioned and untreated exosomes, followed by GelMA hydrogel delivery, provides a useful framework for studying engineered extracellular vesicles in bone repair.

• Measuring Drug Response Beyond Relative Viability

  2026-08-16

  Hannah R. Schwartz’s dissertation distinguishes relative viability from fractional viability to clarify whether an anticancer treatment primarily slows proliferation, induces cell death, or does both. Its central practical implication is that drug-response studies should measure growth inhibition and killing as related but noninterchangeable outcomes.

• Oridonin, Inflammation, and Esophageal Cancer

  2026-08-15

  This 2025 Frontiers in Oncology study examines how oridonin may counter chemically induced esophageal cancer by suppressing the TLR4/NF-κB/NLRP3 inflammatory axis. Its value lies in integrating histopathology, systemic inflammatory measurements, blood-cell indices, and tissue-level molecular assays, while its findings remain preclinical and mechanistically associative.

• Ziprasidone HCl: A Translational Research Bridge

  2026-08-15

  Ziprasidone HCl offers a distinctive translational opportunity at the intersection of neuroscience research and oncology. Its established receptor pharmacology can be studied alongside reported GOT1 inhibition, while impurity control, formulation strategy, and exposure-matched experimental design determine whether this dual profile can generate credible therapeutic hypotheses.

• Endogenous BAX–BAK Mosaic Rings in Apoptosis

  2026-08-14

  The 2024 Cell Death & Differentiation study uses live- and fixed-cell STED microscopy to show that endogenous BAX and BAK assemble into heterogeneous, variable-size rings on apoptotic mitochondria. Its finding that BAK is recruited before BAX and that either protein can form rings independently refines current models of mitochondrial outer membrane permeabilization.

• Bufalin Targets STK33 in Triple-Negative Breast Cancer

  2026-08-14

  A 2025 Advanced Science study identifies serine/threonine kinase 33 (STK33) as a direct binding partner and degradation-sensitive driver of triple-negative breast cancer. By combining target discovery, biophysical validation, genetic perturbation, animal models, and patient-derived organoids, the work provides a mechanistic framework for evaluating Bufalin-centered TNBC research workflows.

• Lysosomal Exocytosis in MPS IVA Cartilage

  2026-08-13

  A 2026 study in Disease Models & Mechanisms links enhanced lysosomal exocytosis with cartilage pathology in a zebrafish model of mucopolysaccharidosis type IVA (MPS IVA). Its key contribution is showing that lysosomal dysfunction can alter cathepsin activity, glycosaminoglycan distribution and TGFβ/BMP signaling in a disease-specific manner, extending explanations beyond substrate storage alone.

• Native Protein Gel Electrophoresis: K4142 Guide

  2026-08-13

  Learn how native protein gel electrophoresis can complement cell viability, proliferation, and cytotoxicity assays by preserving protein structure and activity. This scenario-based guide explains when Basic Protein Native PAGE Gel Preparation and Electrophoresis Kit (SKU K4142) is appropriate, how to optimize it, and how to interpret native gel data.

• FH1 Small Molecule for iHep Maturation

  2026-08-12

  FH1 is a small molecule for improving functional readouts during iPS cell differentiation to hepatocytes. Product information reports twofold higher albumin secretion, larger hepatocyte-like colonies, increased CYP3A4 levels, and reduced AFP secretion in iHep cultures.

• MK 0893: Mapping GCGR Antagonism to Assays

  2026-08-12

  MK 0893 is a glucagon receptor antagonist whose extra-helical binding mode connects receptor structure with practical cAMP and glucose assays. This guide explains how its pharmacology, selectivity, formulation, and in vivo evidence should shape experimental design.

• KR-12 and LL-37: Biocidal and Antibiofilm Evidence

  2026-08-11

  The 2017 Frontiers in Microbiology study compared LL-37 with the truncated peptides KE-18 and KR-12 across planktonic and biofilm models of Candida albicans, Staphylococcus aureus, and Escherichia coli. Its central insight is that minimum inhibitory activity and biofilm prevention are separable phenotypes, showing why short host-defense peptide fragments require endpoint-specific evaluation.

• 25-Hydroxycholesterol Reprograms Immunosuppressive TAMs

  2026-08-10

  Xiao et al. identify CH25H-derived 25-hydroxycholesterol as an immunometabolic checkpoint that activates lysosomal AMPKα and strengthens STAT6-dependent ARG1 production in tumor-associated macrophages. The work connects oxysterol compartmentalization, macrophage metabolism, and T-cell exclusion, while showing that CH25H targeting can improve anti-tumor responses alone or with anti-PD-1 therapy.

• Thioguanine in EV71 Research: Assay-to-Mechanism

  2026-08-09

  Thioguanine, also known as 6-thioguanine, is examined here through an assay-to-mechanism framework centered on EV71 replication, BIRC3-mediated autophagy, and translational controls. Learn how to distinguish antiviral activity from cytotoxicity while connecting purine metabolism, epigenetic biology, and practical compound handling.

443 records 7/30 page Previous Next First page 上5页 678910 下5页 Last page